Originally appearing here. Nature News published a piece on Griffiths’ follow-up to his human psilocybin research. MAPS President Rick Doblin posted a comment in response to the piece which is included …
Originally appearing here. A web exclusive piece published online by Newsweek discusses Griffiths’ psilocybin research and his piece containing guidelines for human research with psychedelic compounds, …
Originally appearing here. Wired just published a story on Roland Griffiths’ recently published 14-month follow-up to his initial human psilocybin study, and discusses another paper that he and collaborators …
Originally appearing here. Roland Griffiths and his study of psilocybin have made the news again, as recounted in this Associated Press news report, with the appearance of a 14-month follow-up to his original …
Dear Editor, The obituary for Albert Hofmann, the inventor of LSD who died April 29 at age 102, reported that LSD research was stopped in the early 1970s and never resumed. Actually, a protocol evaluating …
Published on 8 May, 2008 From The Economist HIS first experience was “rather agreeable”. As he worked in the Sandoz research laboratory in Basel in Switzerland on April 16th 1943, isolating …
By Rick Doblin Published in Google News Inventions don’t get to pick their inventors, but if they did, LSD couldn’t have picked a better inventor than Albert Hofmann. Albert was already mystically …
By BENEDICT CAREY From the New York Times On the afternoon of Jan. 11, Albert Hofmann, the chemist who discovered LSD, had about a dozen friends and family up to his glass-walled home in the mountains …
From the National Post (Canada) Published on May 01, 2008, 1:47 PM EST By Colby Cosh The Swiss chemist Albert Hofmann, who died on Tuesday at the age of 102, assembled a remarkable track record as an investigator …
Read this letter from MAPS researcher Peter Gasser discussing his recently approved Swiss LSD-End of life study. Dear friends and colleagues, Yesterday (Dec. 5) I received the approval form of the Swiss …
Dr. Peter Gasser’s MAPS-sponsored study evaluating LSD-assisted psychotherapy for subjects with anxiety secondary to advanced-stage illness received final approval from the BAG (Swiss DEA) on December …
In September, MAPS submitted an application to FDA for a new study evaluating psilocybin-assisted psychotherapy for subjects with end-of-life anxiety secondary to advanced-stage melanoma. On October 18, …
